Ventyx’s CV drug reduces cardio risk biomarker by nearly 80% in 1st week of phase 2 study
Ventyx Biosciences’ cardiovascular disease drug cut levels of a biomarker for stroke and other serious risks by almost 80% within a week. The San Diego-based biotech has been evaluating the…